<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040427</url>
  </required_header>
  <id_info>
    <org_study_id>16-960</org_study_id>
    <nct_id>NCT03040427</nct_id>
  </id_info>
  <brief_title>The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis</brief_title>
  <official_title>The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Jaber</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators postulate that F-18 florbetapir will show improved detection of cardiac
      amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's
      disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in
      myocardium prior to current non-invasive diagnostic measures, particular electrocardiography
      with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18
      florbetapir and assess its correlation between standard non-invasive diagnostic modalities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of positive studies as determined by the tracer uptake by the heart.</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with extracardiac transthyretin (TTR) or Light Chain (AL) amyloid deposits with positive Florbetapir-18 PET scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of clinical symptoms of cardiac amyloidosis by conventional cardiac testing.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine that if florbetapir F18 scan can be used to detect the early amyloid involvement of the heart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of F-18 florbetapir PET scan with TcPYP scan.</measure>
    <time_frame>1 month</time_frame>
    <description>Correlation of TcPYP nuclear scintigraphy with F-18 florbetapir PET scan in patients with ATTR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>AL or TTR type amyloidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will undergo F-18 florbetapir PET scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 florbetapir</intervention_name>
    <description>Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).</description>
    <arm_group_label>AL or TTR type amyloidosis</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>Florbetapir-fluorine-18</other_name>
    <other_name>18F-AV-45</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis

          2. Patients with a ratio of affected to unaffected free light chains &gt;5 or free light
             chain difference of &gt;50

        Exclusion Criteria:

          1. Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall
             thickness â‰¥ 13mm

          2. Contraindication to florbetapir or its components

          3. Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Nissen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wael Jaber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wael Jaber, MD</last_name>
    <phone>216 444-8305</phone>
    <email>JABERW@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Jarosz</last_name>
    <phone>216 445-6572</phone>
    <email>JAROSZM@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Main Campus)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael jaber, M.D.</last_name>
      <phone>216-444-8305</phone>
      <email>JABERW@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Asad Ikram, M.D.</last_name>
      <phone>216-636-6148</phone>
      <email>ikrama@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Wael Jaber, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mazen A Hanna, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asad Ikram, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett W Sperry, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Wael Jaber</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>F-18 florbetapir</keyword>
  <keyword>Amyvid</keyword>
  <keyword>PET scan</keyword>
  <keyword>Early detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

